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Osorio, Milne et al. (2014)  reported a SNP, rs2304277, in the OGG1 gene, with 
evidence of potential association with increased ovarian cancer risk in BRCA1 germline 
mutation carriers (p=4.8x10-3). The protein OGG1 is a main player in the DNA BER 
pathway, responsible for recognizing and excising oxidized guanines (8-oxoG).  
In the literature, oxidative stress has been well characterized to have a natural 
site-specific preference for guanines, in which telomeric DNA is enriched due to several 
TTAGGG repeats.  8-oxoG is highly mutagenic and affects DNA replication, and at the 
telomere level it can impair the recruitment and affinity of the shelterin complex proteins. 
This complex caps and protects telomeres from aberrant chromosomal rearrangements. 
Not only, when not properly corrected, 8-oxoG can give rise to ssDNA breaks. 
Therefore, telomeres are more susceptible to this kind of damage, and disruption of the 
normal telomere function and length can result in carcinogenesis, as a consequence of 
genomic instability. Hence, given the role of OGG1 and telomeres composition, we 
aimed to explore whether the increase of cancer risk in the carriers of rs2304277 
(together with a germline mutation in the BRCA gene), might be due to an altered 
OGG1 function, which could accelerate the telomere shortening, resulting from a 
weaker response upon oxidative stress harms.  
For the functional characterization of the polymorphism, the experimental 
approach was based on the evaluation of the OGG1 mRNA expression levels by qPCR 
and measurement of telomeres length by High Throughput Q-FISH of the different 
OGG1 genotypes and BRCA1/2 mutation status from peripheral blood samples. Very 
preliminary results, suggest that the variant leads to a decrease in OGG1 mRNA levels 
which, and together with a mutation in BRCA gene might contribute to an accelerated 
telomere shortening. These results might explain, in part, the increase of an individual’s 
lifetime risk of developing cancer when harbouring both genetic conditions. 
 
 
 
Keywords: OGG1, SNP, BRCA, Ovarian cancer, telomeres shortening, oxidative stress 
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Recentemente, Osorio, Milne et al. (2014) realizaram uma análise 
compreensiva de dezoito genes que envolvem a via de reparação de DNA Base 
Excision Repair (BER), numa ampla série de portadores de uma mutação na linha 
germinal em um dos genes de elevada penetrância BRCA1 ou BRCA2 provenientes do 
consórcio CIMBA (Consortium of Investigators of Modifiers of BRCA1 and BRCA2). A 
escolhida via de reparação de ADN, BER, foi feita com base no conceito de letalidade 
sintética entre membros da via BER, como PARP1 (Poly ADP ribose polymerase), 
BRCA1 e BRCA2. 
Desses 18 genes escolhidos, foram identificados onze SNPs (polimorfismos de 
base única), com evidências de associação com o aumento de risco para o  
desenvolvimento de cancro da mama e/ou dos ovários. Desses onze SNPs, cinco 
localizam-se em genes de ADN glicosilases, e aqueles com mais fortes evidências de 
associação ao risco de desenvolver os referidos cancros, localizam-se em dois genes 
de ADN glicosilases: rs1466785 no gene NEIL2 (endonuclease VIII-like2) (HR: 1.09, 
95% CI (1.03–1.16), p= 2.761023) para o cancro da mama em portadores de uma 
mutação no BRCA2, e rs2304277 no gene OGG1 (8-guanine DNA glycosylase) (HR: 
1.12 95%CI: 1.03–1.21, p= 4.861023) para o cancro dos ovários em portadores de uma 
mutação no gene BRCA1. Este estudo focou-se e contribuiu para a caracterização 
funcional do polimorfismo rs2304277 no gene OGG1, de forma a estabelecer uma 
possível explicação para a sua associação com o aumento de risco de desenvolver 
cancro, mais concretamente cancro do ovário em portadores de uma mutação na linha 
germinal no gene BRCA1.  
8-oxoguanina DNA glicosilase, OGG1, é uma enzima com um papel 
fundamental nas etapas primárias de ação da via de reparação BER, sendo 
responsável por fazer o reconhecimento e excisão de bases quimicamente alteradas 
que perturbam minimamente a hélix do ADN, no caso concreto desta ADN glicosilase, 
as guaninas oxidadas: 8-oxodeoxyguanosina (8-oxoG). Na literatura, está muito bem 
descrita e caracterizada uma tendência natural do stress oxidativo sobre as guaninas, 
que torna o ADN telomérico mais suscetível e sensível a este tipo de agressão, uma 
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vez que são estruturas enriquecidas em guaninas, devido às suas várias repetições da 
sequência “TTAGGG”.  
8-oxoG é o produto mais comumente gerado por stress oxidativo e é altamente 
mutagénico pois possuí uma grande propensão em emparelhar com adeninas, 
podendo conduzir a transversões GC para TA durante a replicação do ADN. Embora 
essa transversão possa ser não-sinónima, alterando o produto final da proteína e, num 
cenário mais drástico, a sua função, a substituição de guaninas por timinas diminui o 
recrutamento e afinidade das proteínas que cobrem e protegem fisicamente os 
telómeros. O conjunto destas proteínas forma um complexo denominado de shelterin.  
As proteínas do complexo shelterin impedem o reconhecimento das 
extremidades cromossomais, conhecidas por telómeros, como quebras intra-
cromossomais formando uma configuração fechada destas estruturas. Desta forma, os 
mecanismos de reparação de ADN danificado não são ativados e, consequentemente, 
os telómeros não são sujeitos a fusões cromossómicas aberrantes, o que levaria à 
instabilidade cromossómica. Na literatura, está muito bem descrito que telómeros 
criticamente curtos podem funcionar como um promotor da carcinogénese devido à sua 
subsequente instabilidade cromossómica.  
No entanto, este não representa o único problema relativo às guaninas 
oxidadas. Algumas ADN polimerases, as de maior fidelidade, poderão encontrar 
dificuldades na replicação de ADN na presença de 8-oxoG, uma vez que guaninas 
oxidadas conduzem a uma ligeira modificação na cadeia de ADN. Comprometendo 
assim a replicação normal do ADN e possivelmente a dos telómeros, podendo 
contribuir ainda para um encurtamento dos telómeros mais acelerado. A disrupção do 
tamanho normal dos telómeros e da sua normal função pode resultar em 
carcinogénese, como consequência da instabilidade genómica advinda de telómeros 
curtos que acabam por perder a proteção do complexo shelterin. Telómeros 
criticamente curtos têm sido também descritos como promotores de tumores. As 
quebras de ADN, mais especificamente em apenas em uma das cadeias (ssDNA) 
podem também acontecer quando a intervenção da via BER não é corretamente 
executada ou concluída. Os sítios abásicos provocados pela intervenção BER 
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fragilizam o ADN facilitando a sua quebra. Quebras de ADN de cadeia simples são 
assim as maiores responsáveis pelo encurtamento acelerado de telómeros, segundo 
von Zglinicki, Pilger et al. (2000).  
ADN oxidado é a maior fonte de danos de ADN, e o stress oxidativo poderá vir 
tanto de fontes endógenas (espécies reactivas de oxigénio provindas do metabolismo 
celualr) como exógenas (elementos patogénicos ou radiação ionizante). O que 
propencia a tumourigénese é o desequilíbrio entre as espécies reativas de oxigénio 
(ROS) e as defesas antioxidantes, tal como OGG1. Resumidamente, os telómeros são 
estruturas mais suscetíveis à oxidação, devido ao seu conteúdo rico em guaninas que 
são entre as bases, as preferencialmente oxidadas. As consequências de 8-oxoG no 
ADN telomérico podem promover uma disrupção no tamanho e função dos telómeros 
conduzindo a um encurtamento acelerado e crítico dos telómeros, destabilizando a 
homeostase cromossómica levando à génese tumoral.  
Portanto, dado o papel de OGG1 no reconhecimento e correção das 8-oxoG e 
a composição enriquecida dos telómeros em guaninas, procurámos explorar se o 
aumento de risco de desenvolver cancro nos indivíduos portadores do polimorfismo 
rs2304277 no gene OGG1 e uma mutação nos genes BRCA1/2 se deve a uma 
perturbação na eficácia da ação da enzima OGG1, que poderá favorecer um 
encurtamento de telómeros mais acelerado, como resultado de uma resposta alterada 
às consequências provocadas pelo stress oxidativo.  
Para a caracterização funcional do polimorfismo, a abordagem experimental foi 
feita com base na avaliação dos níveis de expressão de mRNA de OGG1 por qPCR e 
medição do tamanho dos telómeros (TL) por High Troughput Q-FISH para os diferentes 
genótipos de OGG1 (wild type ou portadores da variante) e BRCA status de amostras 
de sangue periférico. Resultados muito perliminares, sugerem que a variante possa 
levar à diminuição dos níveis de mRNA de OGG1 que, juntamente com uma mutação 
no gene BRCA contribuí a um encurtamento dos telomeros mais acelarado, o que 
poderá explicar em parte, o aumento de risco de desenvolver cancro em pessoas que 
abrigam ambas as condições genéticas. 
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Sendo o cancro uma doença poligénica, são então importantes estudos como 
este, feitos com  base na descoberta e caracterização de variantes genéticas que 
possam contribuir para o desenvolvimento de cancro, contribuindo para uma melhor 
avaliação de risco da população saudável. 
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Abbreviations are displayed in alphabetic order  
 
8-oxoG 8-oxodeoxyguanosine 
53BP1 53 binding protein 1 
A 
A  Adenine 
AP Apurinic/apyrimidinic 
APE Apurinic or apyrimidinic endonuclease 
B 
BER Base excision repair 
BRCA1 Breast cancer susceptibility gene 1 
BRCA2 Breast cancer susceptibility gene 2 
BRCAX Breast cancer susceptibility gene X 
C CIMBA 
Consortium of investigators of modifiers of BRCA1 
and BRCA2 
D 
DDR DNA damage response 
DHPLC High-performance liquid chromatography 
dsDNA  Double-stranded DNA 
F 
F Forward 
FBC Familial breast cancer 
FBOC Familial breast and ovarian cancer 
G 
G Guanine 
GWAS Genome-wide association studies 
 Page | 3  
 
 
H HR Homologous recombination 
L LD Linkage disequilibrium 
M 
miRNA MicroRNA; micro ribonucleic acid 
MRN Mre11-Rad50-Nbs1 complex 
mRNA Messenger ribonucleic acid 
N 
NEIL2 Endonuclease VIII-like2 
NHEJ Non-homologous end joining 
O OGG1 8-oxoguanine DNA glycosylase 
P 
PARP1 Poly ADP ribose polymerase 
PCR Polymerase Chain Reaction 
POT1 Protection of telomeres 1 
Q 
Q-FISH Quantitative Fluorescence in situ hybridization  
qPCR Quantitative Polymerase Chain Reaction  
R 
R Reverse 
RAP1 Repressor and activator protein 1 
ROS Reactive oxygen species 
RT-PCR Reverse Transcription Polymerase Chain Reaction 
S 
SNP Single-nucleotide polymorphism 
ssDNA Single-stranded DNA 
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T 
TIN2 TRF1-interacting protein 2 
TL Telomere length 
TRF1 Telomeric repeat-binding factor 1 
TRF2 Telomeric repeat-binding factor 2 
TPP1 POT1- and TIN2 interacting protein  
U  UTR Untranslated region 
W wt Wild type 
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Concepts are displayed in alphabetic order  
 
C Causal SNP The SNP which is affecting a trait/phenotype/disease 
F 
Fine Mapping 
Pos-genotyping analysis with greater resolution that 
searches for the causal SNP at a susceptibility locus 
Five-year survival 
rate 
Percentage of patients who are alive at least five years 
after the diagnose of their cancer 
Five-year relative 
survival rate 
A more accurate prognosis with a percentage of a group of 
patients with a certain type and stage of cancer, who are 
alive at least five years after the diagnose of their cancer 
H 
Haplotype 
A set of alleles in LD inherited in a dependent way, as a 
unit 
HapMap Project 
Catalogue that aimed to map the haplotypes of the human 
genome, describing what there variants are and how they 
are distributed among populations 
I Incidence 
Number of new cases of a specific disease occurring 
during a certain period in a population 
L 
Linkage 
Disequilibrium 
Correlation of neighbouring alleles at different loci, that are 
inherited dependently, reflected in haplotypes. In other 
words, individuals who carry a specific SNP are often 
predictably carrying specific nearby alleles that are in LD  
M 
Major Allele Represents the commonest allele in a given population  
Minor Allele Represents the least common allele in a given population 
P Polymorphism Genetic variation present in a population 
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Polygenic Model 
Describes a trait/phenotype/disease which is influenced 
not by a single gene but for more 
Prevalence 
Total number of cases with a specific disease in a 
population at a certain period 
R Risk Factors 
Anything that might affect the chance of an individual of 
getting the disease 
S 
Synthetic Lethality 
Combination of perturbations in at least two genes/proteins 
leads to cellular death 
SNP 
DNA sequence variation occurring in at least 1% of the 
population. Polymorphic site which is diallelic, having a 
major allele and a minor allele 
Susceptibility 
Likelihood to be influenced or harmed by a particular 
condition 
T TagSNP 
Representative SNP in a determined region of the genome 
with high LD (r2 ≥ 0.8) with a group of other SNPs: 
haplotype 
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3.1. Telomeres 
Derived from the Greek words telos and meros meaning “end” and “part”, 
respectively, telomeres are the structures that caps the chromosome ends representing 
a crucial role in the genome integrity maintenance (Aubert and Lansdorp 2008). 
Discovered and described for the first time in the early 1930’s by Herman Muller  and 
Barbara McClintock (Mason and Perdigones 2013). 
These eukaryotic specialized nucleoproteins structures prevent abnormal 
chromosomal fusion or rearrangements shielding the natural ends of linear 
chromosomes that resemble DNA breaks (Rhodes and Giraldo 1995, O'Sullivan and 
Karlseder 2010). Since linear DNA fragments are toxic to mammalian cells, enzymes 
that degrade or repair those fragments are activated, and inappropriate repair can lead 
to genomic instability and, eventually, carcinogenesis (O'Sullivan and Karlseder 2010). 
Hanahan and Weinberg (2011) include genome instability in the ten cancer hallmarks. 
Telomeres are therefore vital structures for maintenance of genomic integrity.  
Mammalian telomeres are made of long stretches of double-stranded DNA 
TTAGGG repeats (9-15kb in humans) and at the 3’ end are 50-300 nucleotide single-
stranded repeats, the so-called G-overhang (Figure 3.1 and Figure 3.2, left) (O'Sullivan 
and Karlseder 2010). Telomeric-loop, also referred as T-loop, is the end structure in 
telomeres that works as a protective cap masking the natural ends of the telomeres 
from the DNA damage response (DDR) machinery, through a closed configuration 
(O'Sullivan and Karlseder 2010).  
 
 
 
 
 
 
Loop 
ssDNA dsDNA T-loop 
G-overhang 
Folding 
Figure 3.1 T-loop structure. The G-overhang (ssDNA) bends into the 
double-stranded DNA (dsDNA) telomeric repeat array. Adapted from de 
Lange (2005) 
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3.1.1. SHELTERIN COMPLEX 
Besides this T-loop configuration, the distinction of telomeres from intra-
chromosomal breaks is also ensured by the recruitment of the shelterin complex protein 
to the TTAGGG telomeric repeats. The shelterin complex has a wide and vital role in 
the telomere length regulation and protection (Figure 3.2, right) (Liu, O'Connor et al. 
2004, de Lange 2005, O'Sullivan and Karlseder 2010). These proteins cap the 
chromosome ends hiding them from the surveillance of the DDR, avoiding an 
inappropriate action from the DNA repair pathways, which would process telomeres 
ends as intra-chromosomal breaks and start fusing them (de Lange 2005). Shelterin 
proteins also have a part in the intracellular signalling for cell proliferation, DNA repair 
and recombination regulation (Xin, Liu et al. 2008). 
This complex consists of six proteins: telomeric repeat-biding factor 1 and 2 
(TRF1 and TRF2); repressor and activator protein 1 (RAP1); TRF1-interacting protein 2 
(TIN2); protection of telomeres (POT1) and POT1- and TIN2 interacting protein (TPP1) 
(Figure 3.2, right) (Xin, Liu et al. 2008, O'Sullivan and Karlseder 2010). TRF1, TRF2 and 
POT1 recognize and bind to TTAGGG repeats and interrelate with the rest of the 
shelterin proteins: TIN2 TPP1 and RAP1, allowing cells to differentiate telomeres from 
DNA damaged sites (de Lange 2005).  
 
 
 
 
 
 
3.1.2. TELOMERE SHORTENING  
Losing around 100-200 bp in every division (Aubert and Lansdorp 2008), 
somatic cells can only undergo a limited number of divisions before telomeres become 
Figure 3.2 Structure of human telomeres consists in many kilobases of TTAGGG repeats that extend in the 
3’ direction, forming the G-overhang strand (left image). Shelterin complex (TRF1, TRF2, RAP1, TIN2, POT1 
and TPP1) covers the double- and single-strand telomeric DNA, protecting these structures (right image). 
Adapted from O'Sullivan and Karlseder (2010).  
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dysfunctional (< 3Kb) and establish replicative senescence (Figure 3.3). Telomeres are 
therefore vital to preserve genetic information and integrity in each cell division (Sun, 
Tan et al. 2015)  
Telomerase is a ribonucleoprotein, which binds to the first few nucleotides in the 
3’ end of telomeres, and adds the six-nucleotide repeating sequence: 5’-TTAGGG-3’, 
using RNA primers as template. Like that, it elongates telomeres reversing their 
shortening, a normal consequence of cell division (Weinrich, Pruzan et al. 1997, Cong, 
Wright et al. 2002). 
During normal cell division, somatic cells do not express or have low expression 
of telomerase and therefore, have progressive telomere shortening (Hodes 1999), but is 
strongly active in germ, stem and most of the tumour cells, in order to prevent telomere 
attrition (Mason and Perdigones 2013).   
Critically short telomeres can lose their shelterin complex bond domains, and as 
mentioned above, activate DDR mechanisms. To avoid recognition of critically short 
telomeric ends as double-stranded (dsDNA) breaks and inappropriate end-to-end DNA 
fusions, the cell gets into a terminal arrest, known as replicative senescence (Aubert 
and Lansdorp 2008, Munoz-Espin and Serrano 2014, Sun, Tan et al. 2015). This occurs 
when a cell reaches its limit of replicative lifespan being a major tumour suppressor 
mechanism together with apoptosis (Collado, Blasco et al. 2007, Munoz-Espin and 
Serrano 2014).  
Cells in which this tumour suppressor mechanism, replicative senescence, does 
not work properly, might go through inappropriate DNA fusions and rearrangements, 
which can favour consequently, translocations, aneuploidy and amplifications/deletions 
(Figure 3.4) (Artandi and DePinho 2010). These phenomena of aberrant 
rearrangements lead to chromosomal instability, which is one of the two most important 
cancer hallmark (Hanahan and Weinberg 2011).  
There are several retrospective case-control and longitudinal studies suggesting 
that short telomeres may predispose to cancer (Wu, Amos et al. 2003, Shao, Wood et 
al. 2007, Wentzensen, Mirabello et al. 2011, Zhang, Chen et al. 2015) 
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Figure 3.3 Telomere Length dynamics in germ, stem, somatic and tumour cells. 
Adapted from Mason and Perdigones (2013). 
T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.2.1. OXIDATIVE STRESS AND ITS CONTRIBUTE TO TELOMERE CRISIS 
Besides the normal cell division and aging, oxidative stress is also a contributor 
to telomere shortening/crisis due to its natural site-specific preference to oxidize 
guanines, for which telomeric DNA is enriched (TTAGGG repeats) (Oikawa and 
Kawanishi 1999).  
Oxidized guanines, also called 8-Oxodeoxyguanosines (8-oxoG), are the most 
common product generated by oxidative stress, and are highly mutagenic because of 
Figure 3.4 Critically short telomeres can undergo into 
aberrant fusions, promoting chromosome breaks, 
translocations, aneuploidies, amplifications and deletions. 
Adapted from Mason and Perdigones (2013). 
and/or translocations, aneuploidy, 
amplifications or deletions 
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their propensity to mismatch with Adenine promoting GC-to-TA transversions during 
DNA replication (von Zglinicki 2002). Despite the fact that those transversions can be 
non-synonymous, modifying the final product of a protein and its function, the loss of 
guanines to thymines, at telomeres level, decreases the recruitment and affinity of the 
shelterin complex, possibly leading to aberrant and inappropriate end-to-end fusions, 
since the shelterin complex is no longer able to mask the telomeric ends from the DDR 
(Figure 5) (von Zglinicki 2002, Klaunig, Kamendulis et al. 2010, Wang, Rhee et al. 2010, 
Georgakilas 2012). Cellular processes such as apoptosis, ageing and chromosomal 
stability maintenance are affected by the loss of the shelterin complex, insofar as 
mediators of the telomeres signalling (Figure 3.5) (Oikawa and Kawanishi 1999, von 
Zglinicki 2002, Coluzzi, Colamartino et al. 2014). 
Additionally, 8-oxoG can contribute to disturb telomere homeostasis also by 
affecting the DNA replication, as they can lead to change in the normal DNA molecule 
conformation, which can hinder the binding of the high-fidelity DNA polymerases during 
normal replication, and possibly disrupting telomere length and its function (Figure 3.5) 
(Oikawa and Kawanishi 1999, von Zglinicki 2002, Wang, Rhee et al. 2010). 
Several studies have shown higher levels of 8-oxoG in various human cancers: 
Miyake, Hara et al. (2004), Weiss, Goode et al. (2005), Diakowska, Lewandowski et al. 
(2007) and Tanaka, Fujita et al. (2008). 
Oxidative stress also gives rise to DNA breaks, mostly single-stranded DNA 
(ssDNA) breaks, either generated as a consequence of the disintegration of the 
oxidized sugar or the intervention of DNA Base Excision Repair (BER) pathway over the 
oxidized bases that create abasic sites (Oikawa and Kawanishi 1999, von Zglinicki, 
Pilger et al. 2000, von Zglinicki 2002, Klaunig, Kamendulis et al. 2010, Georgakilas 
2012). A study (von Zglinicki, Pilger et al. 2000) has shown that the accumulation of 
ssDNA breaks is the major responsible for telomere shortening in human fibroblasts.   
Oxidized DNA is the major source of DNA damage in living organisms, and both 
endogenous and exogenous sources of oxidative stress can contribute to 
carcinogenesis when the load of Reactive Oxygen Species (ROS) is not counteracted 
by the antioxidant defences (Figure 3.6) (Klaunig, Kamendulis et al. 2010). In 
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conclusion, since telomeric DNA is a highly protected structure its repair is not that 
efficient, making it more vulnerable to aggressions, e.g. oxidative stress, as the proteins 
that cover it hamper the DNA repair machinery access (von Zglinicki 2002, Coluzzi, 
Colamartino et al. 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.6 ROS effect in cells and its role in cancer 
development  
Figure 3.5 Oxidative stress effects over telomeres. 
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3.2. Base Excision Repair pathway 
The BER pathway is the principal responsible for the correction of oxidative 
lesions in the DNA, being the unique process specialized in the single-base lesions 
reparation with only four core proteins: a DNA glycosylase, an apurinic or apyrimidinic 
endonuclease (APE), a DNA polymerase and a DNA ligase (Kow 1994, Kim and Wilson 
2012).  BER action mode is the following: the damaged base is excised by the DNA 
glycosylase creating an apurinic/apyrimidinic (AP) site; the AP endonuclease cleaves 
the AP site generating a 3’OH and 5’ deoxyribose phosphate terminus, which is forward 
filled by the DNA polymerase and sealed by the DNA ligase (Figure 3.7) (Kow 1994, 
Mendelsohn 2008, Kim and Wilson 2012).   Additionally, BER pathway also corrects 
damaged bases by alkylation (Sedgwick, Bates et al. 2007) and deamination  (Kavli, 
Otterlei et al. 2007). All BER repair processes restore the appropriate DNA base with 
high accuracy, maintaining the template function of the DNA and avoiding the decay of 
genetic information (Jacobs and Schar 2012, Kim and Wilson 2012).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Scheme of Base excision Repair pathway action mode. Small 
lesions in DNA are often recognized and corrected by BER mechanisms repair. 
At first the lesion is recognized and flipped out by DNA glycosylase(A), and then  
the phosphodiester backbone of the DNA is cleaved by APE (B). An error-free 
DNA polymerase (Pol-β) fills the gap with the appropriated nucleotide ending with 
DNA ligase sealing the base to the double-stranded DNA restoring the normal 
sequence(C). Adapted from  (Mendelsohn 2008) 
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3.2.1. 8-oxoguanine DNA glycosylase, OGG1 
OGG1, 8-oxoguanine DNA glycosylase, is an enzyme that acts in the early 
steps of the mentioned pathway. First found in yeast (Nash, Bruner et al. 1996) and 
later in humans (Radicella, Dherin et al. 1997), OGG1 is an enzyme which plays a key 
role in the repair of such lesions, making the recognition and excision of the chemically 
modified bases causing minor perturbations in the DNA helix, cleaving the glycosidic 
bond (Jacobs and Schar 2012, Kim and Wilson 2012). Single-base lesions are then 
flipped out generating an abasic- AP-site, being further processed by the subsequent 
enzymes, in order to restore the original DNA sequence before the DNA polymerase 
gets the opportunity to miss-insert an adenine, preventing a transversion mutation 
(Jacobs and Schar 2012). 
Up till now, eleven different DNA glycosylases have been identified in mammals 
which can be divided into distinct superfamilies (Jacobs and Schar 2012). OGG1 is a 
helix-hairpin-helix glycosylase (Figure 3.8) whose respective motif is able to recognize 
both single-strand and double-strand DNA, by hydrogen bond-mediated interactions 
with the DNA-phosphate backbone (Shinmura and Yokota 2001). Such interactions are 
fundamental for DNA glycosylases function.  
The OGG1 gene is localized in the human chromosome 3p25.3 and consists of 
11 exons, covering about 38.275 bp of DNA. Even though with 18 different possible 
transcripts, its principal protein product has 424 amino acids residues with a theoretical 
molecular weight of 4.95kDa (Ensembl 2015).  
Ablation of ogg1 in Saccharomyces cerevisiae leads to the accumulation of G->T 
transversion mutations (Thomas, Scot et al. 1997), and results in telomere base 
damage and length alteration (Lu and Liu 2010). Also, the Ogg1 null mice exhibit 
abnormal level of chromosomal 8-oxoG but are still viable (Klungland, Rosewell et al. 
1999). In humans, there is evidence that non-synonymous polymorphisms in the OGG1 
gene might associate with cancer (Zhou, Li et al. 2015), such as non-small cell lung 
cancer (Duan, Hua et al. 2012) and esophageal cancer (Wang, Gan et al. 2013). 
Moreover, Osorio, Milne et al. (2014) showed an association between a polymorphism 
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in the 3’-untranslated region (UTR) in the OGG1 gene and cancer risk in Breast Cancer 
Susceptibility Genes 1 and 2 (BRCA1 and BRCA2) germline mutation carriers.  
 
 
 
 
 
 
 
 
 
3.3. Cancer 
The denomination of cancer was initially given by the “Father of Medicine”, 
Hippocrates (460 – 370 BC) as karkinos and karkinoma to describe non-ulcer and ulcer 
forming tumours, respectively. This Greek designation for crab was most likely applied 
because of the finger-like projections, which remind the crab legs shape. Later the 
“cancer” domination was given by the roman physician, Celsus (28 – 50 BC), which 
translated the previous Greek words into Latin (ACS 2014).  
Cancer is a common designation for many different diseases (Britannica 2015). 
Although, there are many kinds of cancer, they share this designation because different 
cancers start the same way: an abnormal cell growth out of control behaving like 
autonomous cells (Mendelsohn 2008, NCI 2015). All body cells can effectively become 
into tumour/cancer, but each type has its own characteristics (UK 2015). 
Carcinogenesis is a multistage disease in which not one, but several mutations 
are required. At least three to six mutations seem to be the necessary to reach this 
development (Vogelstein and Kinzler 1993). These mutations have to be acquired by 
Figure 3.8 Structural representation of hOGG1. The 
six helices are coloured in dark blue and the three DNA 
binding loops in yellow. Adapted from (Drohat, Kwon et 
al. 2002) 
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oncogenes and/or tumour suppressor genes, in a way that affects the net rate of cell 
division. According to Land, Parada et al. (1983), at least one mutation in two 
cooperating oncogenes are necessary for a tumourigenic transformation. Not only a 
multistage disease, cancer is also multifactorial, combining genetic and environmental 
factors (Hanahan and Weinberg 2011).  
Before reaching the malignant stage, denominated cancer, tumour cells 
undergo through a series of stages, which in the majority of cases include: a 
hyperplasia (characterized by an increased number of cells in a tissue), dysplasia 
(where the tissue looks abnormal and disorganized but still not invasive, and cells look 
less differentiated). Cancer stage is achieved when tumour cells acquire invasive 
properties (Mendelsohn 2008).   
Hanahan and Weinberg (2011) defined the necessary functional competences 
that a cell needs to contribute to genesis of malignancies: the hallmarks of cancer, 
which allow cancer cells to survive, proliferate and disseminate. Those hallmarks 
include: resistance to cell death; genome instability and mutation; sustenance of 
proliferative signalling; replicative immortality; escape from immune system surveillance; 
evasion of growth suppressors; deregulation of cellular energy; angiogenesis induction; 
inflammation promoted by tumour and activation of invasion and metastasis properties 
(Figure 3.9).  
The acquisition of this set of malignant competences is mainly regulated by 
genomic instability and premalignant inflammation.  The first one involves processes 
that are involved in major reprogramming processes of cell growth/proliferation and 
metabolism, the second allows cancer cells to escape from immune system surveillance 
and antagonistically operates for an enhancement of tumour progression through the 
immune system (Hanahan and Weinberg 2011).  
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3.4. Breast cancer and Ovarian Cancer 
3.4.1. Epidemiology 
Breast: 
According to GLOBOCAN (2012), female breast cancer is by far the most 
frequent cancer, the most common cause of death (Figure 3.10) and the most 
frequently diagnosed cancer among women worldwide, accounting for 23% of all 
women’s malignant cancers.  In 2012, 1,67 million new breast cancer cases were 
diagnosed representing 25% of all diagnosed cancers (GLOBOCAN, 2012).  
The lifetime risk for breast cancer, in the United States, is approximately 1 in 8, 
and 12.3% of worldwide women will be diagnosed worldwide with breast cancer at 
some point during their lifetime (Ghoussaini, Pharoah et al. 2013). 
 With respect to prevalence, in 2011, 2,899,726 women were living with breast 
cancer. The 5-year survival rate is 89.2%. Such a high percentage is influenced by the 
stage at the time of the diagnosis, referring to the extent of cancer, where 61% is 
detected in the localized state (Figure 3.11) (NCI 2015). 
Figure 3.9 Hallmarks of cancer that gives the necessary 
functional competences a cell need to contribute to carcinogenesis. 
Adapted from Hanahan and Weinberg (2011) 
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Ovary: 
As to the incidence in 2012, around 239,000 new cases of ovarian cancer were 
reported, representing nearly 4% of the new cases of women cancer. Ovarian cancer is 
the seventh most common cancer affecting women worldwide, and the 18th overall 
(Ferlay, Soerjomataram et al. 2015).  
Among all cancers of the female reproductive system, ovarian cancer is the one 
that causes more deaths, being the eighth most common cause of cancer death in 
women worldwide. 14 030 deaths were estimated for 2013. The five-year relative 
survival rate is 44%, considering all the stages of diagnosis (Ferlay, Soerjomataram et 
al. 2015). In 2012, 192,446 women were living in the United States with ovarian cancer, 
and approximately 1.3% of women will be diagnosed at some point of their lifetime 
(GLOBOCAN 2012). 
This type of cancer is usually fatal because most of the cases (60%) are 
diagnosed in an advanced stage, when the cancer is already metastasized. The five-
year relative survival rate for this stage is very low, being 28.3% (Figure 3.12) (Cronin, 
Ries et al. 2014). 
 
 
 
 
 
 
 
 
  
 
Figure 3.10 Estimate incidence and mortality rates 
of the different cancers per 100 000 women per year 
(ASR: age-standardised rate). Adapted from 
GLOBOCAN (2012)  
61% 
32% 
5% 
2% 
Localized - Confined to
Primary site
Regional - Spread to
Regional Lymph Nodes
Distant - Cancer has
metastasized
Unknown - Unstaged
Figure 3.11 Pie with the representative 
percentages of the different stages of breast 
cancer at the time of diagnosis. Adapted from 
GLOBOCAN (2012) 
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3.4.2. Risk factors  
The risk factor concept involves anything that might affect the chance of an 
individual of getting the disease (WHO 2015). A risk factor can be environmental or 
even genetic. Evidently, different cancers have different risk factors and different load of 
the relative risk.  
 
Breast: 
Together with gender, i.e. being a woman, the highest risk factor for breast 
cancer is the age, with the incidence rate higher among older women, although, the risk 
increases across all ages until 80 years-old (UK 2015).  
Another risk factor that substantially increases the risk of developing breast 
cancer is personal history of the disease (Figures 2013). The risk is highly correlated 
with the number of affected first-degree relatives: 1.8 times higher for women with one 
first-degree relative affected, 3 times higher with two, and nearly 4 times higher with 3 or 
more affected relatives (Epidemiology 2015). The younger the age of onset of the 
affected relative, the greater the risk for a woman to develop the disease (Figures 2013, 
Epidemiology 2015). 
Up to date, have been identified high-, moderate- and low-susceptibility genes 
that modifies the risk for breast cancer. For instances, mutations in the BRCA1  (Hall, 
Figure 3.12 Percentage of ovarian cancer diagnosed (left) and 5-year relative survival by stage (right). 
Adapted from Cronin, Ries et al. (2014) 
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Lee et al. 1990) and BRCA2  (Wooster, Neuhausen et al. 1994) high-susceptibility 
genes increase the risk for breast cancer, but also to ovarian, and other cancers.  
Deleterious mutations in the BRCA1 gene confer around 65% increase of cumulative 
risk for breast cancer, while deleterious mutations in the BRCA2 gene confers around 
39% (Antoniou, Pharoah et al. 2003, Chen, Iversen et al. 2006, Chen and Parmigiani 
2007, Milne, Osorio et al. 2008).  
It is believed that differences in worldwide incidence rates are due to the 
variability in reproductive patterns, hormonal factors, lifestyle and environmental factors.  
All these factors are partially responsible for modulating the probability of breast cancer 
development throughout a woman’s lifetime. Table 1 briefly introduces some of the 
known risk factors with their relative risk values (Figures 2013, Epidemiology 2015, UK 
2015). 
Ovary: 
Like breast cancer and most other cancers, the risk of developing ovarian 
cancer increases with age. Most of the ovarian cancers are developed after 
menopause. Women who had a first full-term pregnancy after 35 years-old or who never 
carried a pregnancy to term show higher risk. Also, breastfeeding may lower the risk 
(UK 2015).  
Long-term use of hormonal contraceptives, on the contrary of breast cancer 
risk, lowers ovarian cancer risk, and the longer the use the lower the risk. Curiously, risk 
continues lowering for years after stoppage of use.  Oestrogen/hormone therapies after 
menopause show an increased risk of developing ovarian cancer (UK 2015).  
A strong family history of breast and/or ovarian cancer is a very important risk 
factor, where about 1 in 10 ovarian cancers, 10%, are caused by an inherited faulty 
gene, like BRCA1 and BRCA2. The risk increases the number of affected relatives. 
Familial history of other cancers such as breast cancer is also linked to an increased 
risk. Women who have a personal history of breast cancer have an increase risk, as 
well (UK 2015). A germline deleterious mutation in the BRCA1 gene confers 
approximately 39% increase of cumulative risk, while in the BRCA2 gene conferes 
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around 11% (Antoniou, Pharoah et al. 2003, Chen, Iversen et al. 2006, Chen and 
Parmigiani 2007, Milne, Osorio et al. 2008). 
As to lifestyle, a low-fat diet for at least 4 years showed a reduced risk and 
being overweight during pre-menopause increases the risk. While smoking shows a 
slight increase, drinking alcoholic beverages does not seem to increase the risk of 
ovarian cancer overall (UK 2015).  
 
Table 1 Risk factor and its relative risk for breast cancer in women. Relative risk is a comparison of the absolute 
risk of disease among people with a particular risk factor with the risk among people without that risk factor. Relative 
risk higher than 1.0 means the risk is higher among people with the particular risk factor vs. the people without. 
Adapted from (Figures 2013). 
Relative risk Risk factor 
>4.0 Age (65 or older vs. <65 years-old) 
Certain inherited genetic mutations for breast cancer (BRCA1 and/or 
BRCA2) 
Mammographically dense breasts 
Personal history of early breast cancer onset (<40 years-old) 
Two or more first-degree relatives with early onset age 
2.1-4.0 Personal history of breast cancer (40 or older years-old) 
High endogenous estrogen or testosterone levels (postmenopausal) 
High-dose radiation to chest 
One first-degree relative with breast cancer 
1.1-2.0 Alcohol consumption 
Ashkenazi Jewish heritage 
Early menarche (<12 years-old) 
Height (tall vs. short) 
Late age at first full term pregnancy (>30 years-old) 
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Late menopause (>55 years-old) 
Never breastfed 
No full term pregnancies 
Obesity 
Personal history of endometrium, ovary or colon cancer  
Recent oral contraceptive use 
Recent and long-term use of menopausal hormonal therapy  
 
3.4.3. Familial breast and ovarian cancer (FBOC) syndrome 
Cancer is a sporadic disease that occurs due to the accumulation of genetic 
changes, but a small percentage of the cases are considered hereditary. Familial 
cancer is characterized by having a higher number of cancer cases within a family than 
statistically expected, which have a genetic component. While hereditary cancer shows 
a clear pattern of inheritance, clustering of early-onset age and multiple primary cancer 
cases in an individual (Berliner, Fay et al. 2007, Berliner, Fay et al. 2013).  
The first detailed and significantly description about hereditary breast cancer 
was published in 1866 by Paul Broca (1824 – 1880) (van der Groep, van der Wall et al. 
2011). Broca made a pedigree of his wife’s family who suffered from early onset of 
breast cancer, and he suggested that breast cancer could be inherited because four 
generations had breast cancer (Figure 3.13) (van der Groep, van der Wall et al. 2011).  
Up to now high-, moderate- and low-susceptibility genes that increase the risk in 
Familial breast and ovarian cancer (FBOC) have been identified. FBOC  syndrome is 
mostly caused by a germline mutation in high-susceptibility genes BRCA1 
(chromosome 17q21)  (Hall, Lee et al. 1990) and BRCA2 (chromosome 13q12-13) 
(Wooster, Neuhausen et al. 1994) (Figure 3.14). These mutations not only increase the 
risk for breast and ovarian cancer, but also prostate and pancreatic cancer (van der 
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Groep, van der Wall et al. 2011). The overall prevalence of these mutations is 1 in 400 
for BRCA1 and 1 in 800 to BRCA2 (Petrucelli, Daly et al. 2010).  
The penetrance is the most significant clinical aspect in FBOC syndrome, being 
breast and ovarian cancer the predominant phenotypes. The penetrance of these 
mutations vary within families therefore, there is no exact estimate risk for individuals 
harbouring germline BRCA1 and BRCA2 mutations (Petrucelli, Daly et al. 2010). Those 
differences can be due to the type and/or position of the mutation and other genetic 
and/or environment factors (Petrucelli, Daly et al. 2010).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Genealogic tree of Paulo Broca’s wife’s family (1788-1856). Adapted from Gómez (2011) 
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3.4.3.1. Breast cancer susceptibility genes 
Germline mutations in BRCA1 and BRCA2 genes, which predisposes to breast, 
ovarian and even other cancers, explain around 25% of familial breast cancers (FBC). 
There are considerable differences in the manifestation of the disease among all the 
carriers of an inherited mutation in BRCA. This differences, in addition to the fact that 
not all the individuals that inherited a BRCA mutation will develop cancer, suggest the 
existence of other genetic and/or environmental factors modifying the risk of developing 
cancer (Couch, Nathanson et al. 2014).   
Approximately 5% of the FBC cases are due to mutations in high-susceptibility 
genes involved in other familial syndromes such as TP53, PTEN, STK11 and CDH11 
(Borresen, Andersen et al. 1992, Chen, Lindblom et al. 1998, Pharoah, Guilford et al. 
2001, Leggett, Young et al. 2003). 
Figure 3.14 Timeline of hunt for the genetic underpinnings of the familial breast cancer. Adapted from 
Hurst (2014) 
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Moderate penetrance genes include the RAD51C, ATM and CHEK2 genes, 
involved in fanconi and non-fanconi anemias (e.g. (Meindl, Hellebrand et al. 2010)) 
(Meijers-Heijboer, van den Ouweland et al. 2002, Thompson, Duedal et al. 2005)), 
representing 5% of the FBC. 
Recently, 41 low susceptibility polymorphisms were associated to FBC 
(Michailidou, Hall et al. 2013), which together with the 26 polymorphisms previously 
identified explain around 14% of the FBC cases (Ghoussaini, Pharoah et al. 2013) 
Nevertheless, 51% of FBC cases do not have mutations or the alleles described 
above and are thus categorized as BRCAX families. These cases can be explained by a 
polygenic model or by some gene that remains to be identified (Melchor and Benitez 
2013). Figure 3.15 shows the distribution of FBC patients according with their 
mutations/variants in low-, moderate-, high-susceptibility genes/loci. 
Established in 2006, The Consortium of Investigators of Modifiers of BRCA1 
and BRCA2 (CIMBA), provides currently the largest sample size for the study of 
common genetic modifiers of breast and ovarian cancer risk. So far, 94 single-
nucleotide polymorphisms (SNPs) have been associated with low susceptibility to 
breast cancer by Genome-Wide Association Studies (GWAS). (Cox, Dunning et al. 
2007, Easton, Pooley et al. 2007, Stacey, Manolescu et al. 2007, Ahmed, Thomas et al. 
2009, Milne, Benitez et al. 2009, Thomas, Jacobs et al. 2009, Turnbull, Ahmed et al. 
2010, Broeks, Schmidt et al. 2011, Figueroa, Garcia-Closas et al. 2011, Michailidou, 
Hall et al. 2013, Michailidou, Beesley et al. 2015). 
 
 
 
 
 
14% 
5% 
25% 51% 
5% Low Susceptibility Genes
Moderate Susceptibility Genes
High Susceptibility Genes
BRCAX families
Related-syndromes - High
Susceptibility Genes
Figure 3.15 Pie with the representative percentages of familial breast cancer mutations in low-, moderate-, 
high-penetrance genes, BRCAX and related syndromes up to date described that predispose to breast cancer. 
Adapted from (Melchor and Benitez 2013) 
 Page | 28  
 
3.5. Breast Cancer Susceptibility Genes, BRCAs  
 
3.5.1. Function as Homologous Recombination DNA repair members 
BRCA proteins play a very important role in genome and chromosome integrity 
and maintenance, during cell division. It is notable how BRCA-deficient cells accumulate 
espontaneously aberrations in chromosomes’ structure and number, due to impairment 
in Homologous DNA Recombination (HR) pathway, (Venkitaraman 2002, Venkitaraman 
2014). Both BRCA1 and BRCA2 are individually crucial for an efficient HR, a 
mechanism of DNA repair error-free using as template an intact homologous sequence, 
such as sister chromatid (Venkitaraman 2014). 
DsDNA breaks may be create during chromosome duplication thus, BRCA-
deficiency is typically accompanied by dsDNA breaks or aberrant chromosomes 
structure and number since their absent or normal performance leads the cells to 
reroute the DNA reparation to an error-prone mechanism: nonhomologous end joining 
(NHEJ) (Venkitaraman 2014). BRCAs are therefore classified as tumour suppressor 
proteins, with fundamental functions in the genomic stability maintenance. 
The BRCA genes follow the Knudson’s “two-hit” hypothesis (Knudson 1971) 
which postulates that mutation or loss in one of the alleles of a tumour suppressor gene 
is not enough to trigger cancer, being necessary the occurrence of a second “hit” to 
completely inactivate the protein. However, it is known that for BRCA genes just one 
impaired allele can actually affect BRCA normal performance due to haploinsufficiency 
(Cousineau and Belmaaza 2007, Konishi, Mohseni et al. 2011, Nisman, Kadouri et al. 
2013). That phenomenon might increase the susceptibility of the carrier and accelerate 
the loss of the second allele.  
BRCA1 and BRCA2 have many and distinct functions although, in a simplified 
perspective BRCA1 acts in the early steps of HR reparation, whereas BRCA2 stabilizes 
and supports the replication-associated lesions structures. BRCA2 not only plays as HR 
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member but also works in the surveillance of the mitotic spindle assembly checkpoint. In 
Figure 3.16 is possible to see BRCA1 and BRCA2 HR-mediated functions.  
 
 
 
 
 
 
 
Figure 3.16 Some BRCA1 and BRCA2 HR-mediated functions at different stages of  
 
 
 
 
3.5.2. Functional involvement in telomere maintenance  
It has been described that BRCA1/2 have a functional role in the telomere 
maintenance. For instance, previous reports (Xiong, Fan et al. 2003, Ballal, Saha et al. 
2009) suggest that BRCA1 can regulate both telomere length and stability due to its 
interaction with Mre11-Rad50-Nbs1 (MRN) complex (complex that binds to shelterin 
proteins) and telomerase. Regarding BRCA2, Badie, Escandell et al. (2010) have 
shown BRCA2 is with telomeres during the S and G2 cell cycle phases, in order to 
facilitate the loading of RAD51 into telomeres. BRCA2 conditional deletion leads to 
shorter and fragmented telomeres representing telomere fragility (Badie, Escandell et 
al. 2010).  
 Figure 3.16 Some BRCA1 and BRCA2 HR-mediated functions at different stages of cell division. Both BRCA1 
and BRCA2 participate in the G2 checkpoint: BRCA1 helps in the initiation of HR moving 53 Bindingprotein 1 (53BP1) 
and triggers the end resection (represented by the scissors). Thus, BRCA2 binds to the ssDNA and dsDNA junctions 
at the lesion, moving RPA away. During mitosis, BRCA1contributes to mitotic spindle assembly, and BRCA2 watches 
for mitotic checkpoint and participates in the abscission step of cytokinesis. Adapted from Venkitaraman (2014) 
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Together BRCA1 and BRCA2, despite mediating HR also contribute to telomere 
integrity and length. 
 
3.6. Genome-wide association studies, GWAS 
Genome-wide association studies (GWAS) look for genetic variation, such as 
SNPs, that are more frequently present in a group of people with the disease than 
controls. The search for variants/SNPs/polymorphisms can be made without a priori 
information about its genetic function or mechanism, or can be restricted to candidate 
genes. The HapMap project made possible the existence of comprehensive studies 
such as GWAS, where describes common patterns of human DNA sequence variation 
displayed as a haplotype map (International HapMap 2005). GWASs are a good 
approach to identify common alleles with low penetrance in the disease (Figure 3.17), of 
common multifactorial and polygenic diseases (Easton and Eeles 2008).  GWAS are 
used to mapping genomic areas associated with a disease/phenotype (International 
HapMap 2005). 
Systematic studies of common genetic variants are simplified by the linkage 
disequilibrium (LD) phenomenon, because it is possible to obtain a large amount of 
information on genomic variation without complete resequencing and to get an efficient 
selection of tag SNPs, optimizing the association analyses (International HapMap 
2005). 
GWAS are widely used in cancer research, particularly in the commonest 
cancer types such as breast, prostate, colorectal, lung and melanoma (Easton and 
Eeles 2008). 
 
3.6.1. Tag SNPs for association studies 
 
A “tag SNP” is a representative SNP in a determined region of the genome with 
high LD (r2 ≥ 0.8) with a group of other SNPs: haplotype. Like that, it is possible to 
search for an association with a phenotype based on the genotypes: a unique SNP or a 
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combination of various SNPs. LD phenomenon saves the entire genotyping of every 
SNP in a chromosomal region (International HapMap 2005).  
The tag SNPs selection looks for maximum efficiency with the least loss of 
information. Hence, some methods need a single SNP serving as a proxy for others, 
while others use the combination of alleles, or haplotypes, to serve as proxies. The 
causal SNP for a disease is rarely genotyped but a good set of tag SNPs will provide 
association between a genotype and phenotype, which the pinpointed SNP might be in 
LD with the causal one. For the identification of the causal SNP, is necessary a greater 
resolution in the selection of haplotypes blocks as a Fine mapping approach. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.6.2. SNPs in DNA glycosylases genes involved in the BER pathway 
Given the synthetic lethality between members of BER pathway: Poly ADP 
ribose polymerase (PARP1) and BRCA1 and BRCA2, Osorio, Milne et al. (2014) 
performed a comprehensive analysis using a tagging SNP method of 18 genes involved 
in BER pathway in a large series of BRCA1 and BRCA2 mutation carriers from CIMBA 
consortium. 144 tagSNPs were analysed in a sample of 23,463 individuals. 
Figure 3.17 Genome-wide association studies are effective in 
detecting common alleles with low penetrance in a disease. 
Adapted from Eeles, Goh et al. (2014) 
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Evidence of association with breast and/or ovarian cancer was obtained for 
eleven SNPs, of which, five located in DNA gycosylases genes. The strongest 
evidences of was for rs1466785 in the NEIL2 gene (endonuclease VIII-like2) (HR: 1.09, 
95% CI (1.03–1.16), p = 2.761023): associated with breast cancer risk in BRCA2 
mutation carriers, and for rs2304277 in the OGG1 gene (HR: 1.12 95%CI: 1.03–1.21, p 
= 4.861023), associated with ovarian cancer risk in BRCA1 mutation carriers (Osorio, 
Milne et al. 2014). 
These loci should be extensively studied, considering these results. 
 
3.6.2.1. SNP in OGG1 associated with ovarian cancer risk 
An impaired Homologous Recombination DNA repair mechanism, due to a 
BRCA mutation, makes cells critically dependent on other DNA repair machineries such 
as BER pathway. As mentioned above, Osorio, Milne et al. (2014) reported the 
rs2304277 variant in the OGG1 gene with strong evidences of association with ovarian 
cancer in BRCA1 mutation carriers.  Knowing, this SNP was identified by a tagging SNP 
approach, it is possible this is not the causal SNP, but only a SNP in LD with the causal 
one.  
This SNP has two alleles, an Adenine (A) and a Guanine (G), whit the ancestral 
and minor allele being the A allele, present in 35% of the population, according to the 
1000 Genomes project (dbSNP 2015). This polymorphism is located in a 3’UTR, a 
regulatory region that can in many aspects, influence the mRNA molecule in its stability 
or translation. At 3’URT regions, contain specific binding sites for both regulatory 
proteins and microRNAs. Hence, the stability of the mRNA molecule or its translation 
efficiency can be altered. A polymorphism at 3’UTR can, for instance, decrease or 
increase the binding affinity of those microRNA (miRNA) and regulatory proteins, thus 
changing the final product of mRNA and respective translated protein (Barrett, Fletcher 
et al. 2012, Pichon, Wilson et al. 2012). 
OGG1 is a key player in BER pathway, involved in the repair of oxidized 
guanines, bases in which telomeres are enriched. Given the natural preference of 
oxidative stress over guanines, OGG1 role, and telomeres composition, this study 
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followed this line of reasoning to understand and answer whether the increased cancer 
risk is due to a less effective OGG1 response upon oxidative stress, leading to 
accelerate telomere shortening. 
 
  
 
 
 
 
 
 
 
 
 
4. Objectives
 Page | 35 
 
We hypothesized that the association with cancer risk in the carriers of the 
rs2304277 variant might be due to an altered OGG1 function, that could accelerate the 
telomere shortening, resulting from a weaker response upon oxidative stress 
consequences. 
In order to answer the biological question the aims of this study were: 
 
First aim: 
- To investigate whether the rs2304277 variant, located in the 3’ UTR region of 
OGG1 can modify the expression of its messenger ribonucleic acid (mRNA), 
leading to an altered response upon oxidative stress. 
 
Second aim: 
- To investigate whether the presence of the rs2304277 variant in OGG1 alone, or 
in conjunction with the BRCA mutation can modify telomere length, given the role 
of OGG1 in the telomere homeostasis. 
  
 
 
 
 
 
 
 
 
5. Materials & Methods
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5.1. Samples  
The samples mentioned below and used for this study were collected through 
individuals that attended the genetic counselling consultancy for familial cancer in the 
Fuenlabrada Hospital University – Madrid, Spain from 2011 to 2014. Informed consent 
was obtained from all individuals involved in this research project. 
We have followed a cross-sectional approach in a cohort of familiar breast and 
ovarian cancer cases (FBOC) from 101 families, harbouring deleterious mutations in 
BRCA1 and BRCA2 and BRCAX. With BRCAX it is mean cases with familiar history for 
hereditary breast cancer but that do not harbour mutations in any of the identified genes 
for FBC, as reported above in the “Breast Cancer Susceptibility Genes” section. 
Individuals from these families met high risk criteria (Milne, Osorio et al. 2008) and had 
been previously screened for mutations in BRCA1 and BRCA2 by a combination of 
denaturing high-performance liquid chromatography (DHPLC) and direct sequencing as 
previously reported (Diez, Osorio et al. 2003)  
Peripheral blood samples from 223 individuals were used, which 68 (31%) of 
the samples corresponded to controls: healthy women and men with no personal or 
familiar antecedent of cancer and age range from 18 to 84 years old.  45 (20%) and 49 
(22%) individuals harboured a mutation in BRCA1 and BRCA2, respectively, while 61 
samples (27%) a mutation in BRCAX. In the Table 4 it is possible to see the mentioned 
numbers and its relative frequencies within the sample.  
 
5.2. Genotyping 
The genotyping for the polymorphism rs2304277 present in OGG1 gene was 
made in order to know the alleles of which sample included in this study: homozygote 
for the common allele (G/G), heterozygous (GA) or homozygote for the minor allele 
(A/A). 
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5.2.1. DNA extraction 
DNA was extracted from peripheral blood cells of the cited samples using 
MagNAPure LC 2.0 (Roche Diagnostics, Indianapolis, Indiana) manufacturer’s 
conditions.  DNA quantification and quality was assessed by NanoDrop® (ND-1000 
V3.7.1). 
5.2.2. PCR - DNA amplification 
The PCR reagents: HotMaster Taq Buffer with Mg2+ (5PRIME, 1x); dNTPs 
(Thermoscientific, 1.25nU); OGG1 DNA primers (F/R) (SIGMA, 10mM) (Table 2) and 
HotMaster Taq DNA Polymerase (5PRIME, 0,4U/µl) were loaded to 1µl of DNA at 
25ng/µl. The amplification ran at the following conditions:  94ºC for 5 minutes followed 
by 35 cycles at 94ºC for 30 seconds; 65ºC for 45 seconds; 72ºC for 45 seconds and 
72ºC for 5 minutes.  
To check the PCR quality, the products were run in 2% agarose gels to confirm 
a single band (~200bp) and if there was any contamination in the negative controls 
(H2O instead of DNA). 
 
Table 2 Oligonucleotide primers used for PCR 
OGG1 DNA 
Forward 5’ GACCTTTCTCGGACCCCATA 3’ 
Reverse 5’ ACTCCTCCCCATCCCTACC  3’ 
 
5.2.3. Genotyping  
Cleaning up of PCR products for subsequent sequencing was made by 
ExoSAP-IT® (Affymetrix): 2µl of ExoSAP-IT to each 5µl PCR DNA product (diluted into 
1:2) at the following conditions: 37ºC for 15 minutes and 80ºc for 15 minutes. The 
sequencing was performed by the Sanger method in the Genomics Unit at CNIO. 
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5.3. RNA expression analysis 
In line with the hypothesis of this work, this step was made to evaluate whether 
there were different levels of OGG1 mRNA concerning their different genotypes: 
homozygote for the common allele (G/G), heterozygous (GA) or homozygote for the 
minor allele (A/A). 
 
5.3.1. RNA extraction 
 Using TRIzol Reagent (Ambion®, Life Techonogies) according to manufacturer’s 
instructions, RNA was extracted from peripheral blood cells. Both RNA quantity and 
quality were assessed by NanoDrop® (ND-1000 V3.7.1). 
 
5.3.2. Reverse transcription PCR (RT-PCR) 
 RNA at concentration of 1000 ng/µl was reverse transcribed using High 
Capacity cDNA Reverse Transcription kit according to Applied Biosystems (Life 
Technologies) manufacturer’s instructions. Briefly, the mix components: RT buffer (1x); 
dNTPs (4mM); random primers (1x); RNAsin (1U/µl) and finally the MultiScribe Rtase 
(2.5U/µl) were added to the RNA. The thermal cycling conditions started with at 25ºC for 
10 minutes; 37ºC for 120 minutes and a last step at 85ºC for 5 minutes. 
 
5.3.3. Quantitative PCR (qPCR) 
50ng/µl of cDNA obtained in the previous step was loaded with GoTaq® qPCR 
MasterMix (1x); OGG1 cDNA primers (Forward (F)/Reverse (R)) (Table 3) and GAPDH 
cDNA primers (F/R) (SIGMA, 10mM) and CXR as a reference dye (Promega). All the 
mentioned reagents were used following the GoTaq® qPCR Master Mix (Promega) 
following manufacture’s conditions. OGG1-specif primers that did not distinguish 
between the genotypes of the polymorphism were used, and normalization of the 
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samples was carried out with the internal control – GAPDH. The relative expression was 
measured using a comparative Ct method. 
 
Table 3 Oligonucleotide primers used for qPCR 
OGG1 cDNA 
Forward 5’ CTCCACTCCTGCCCTGTG 3’ 
Reverse 5’ AGAGAAAAGGCATTCGATGG 3’ 
GAPDH cDNA 
Forward 5’ CCTGCACCACCAACTGCTTA 3’ 
Reverse 5’ CCATCACGCCACAGTTTCC 3’ 
 
5.4. Telomere Length Measurement 
 
5.4.1. High Throughput Quantitative Fluorescence in situ 
Hybridization(Q-FISH) 
Telomere length (TL) was measured by High Throughput Q-FISH, also known 
by quantitative fluorescence in situ hybridization,  as described in (Canela, Vera et al. 
2007). Mononuclear cells from peripheral blood were cultured in clear-bottom black-
walled 96-well plates (Greiner, Longwood, FL) precoated with 0.001% (wt/vol) (poly)L-
lysine solution (Sigma-Aldrich, St. Louis, MO) for 30 minutes at 37ºC. (Poly)L-lysine was 
removed before the addition of cells (30 000 – 90 000 cells/well). When the 
subconfluency of adherent cells was reached, cells were washed three times with PBS 
and fixed with methanol/acetic acid (3/1, vol/vol) for 1hour at room temperature. After 
the fixation step, cells were hybridized with PNA-tel Cy3-labeled probe together with 
DAPI, and their signals were obtained simultaneously captured at 100x magnification 
using a COHU CCD camera on a Leica DMRA microscope (Leica, Heidelberg, 
Germany).  
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Signal from telomere fluorescence was quantified by TFL-TELO program (Peter 
Lansdorp, Vancouver, Canada) and converted into Kb by external calibration with 
lymphocyte cell lines (L5178Y-S and L5178Y-R) with known TL of 10.2 and 79.7 kb, 
respectively. TL values were normalized by the fluorescence intensity of centromere 
repeats in each nuclei.  
 
5.6. Statistical analysis   
TL (Kb) was adjusted to the age, using the best fit line for male and female 
controls, distinctly. Then, the difference between the actual and the predicted value was 
calculated for each sample. The Kb obtained by High Throughput Q-FISH were 
adjusted following this method: y=-0.0301*(Male age)+11.011; or y=-0.0941*(Female 
age)+13.963 (Annex 1). 
Kolmogorov-Smirnov test was used to evaluate if the data were normally 
distributed or not. The statistical significance of the values given by different 
comparative analysis performed (qPCR and High Throughput Q-FISH) in the present 
study was either measured by Mann-Whitney U test or Unpaired Student t test 
according with their distribution. Where the first mentioned test, Mann-Whitney U test, 
was used for comparative analysis that involved variables not following non-normally 
distributed variants and the second test, Unpaired Student t test, for normally distributed 
variants. 
Test for equality between two regression slopes was calculated using “R” 
according with a predesigned script, used to calculate the statistical significance in the 
analysis of the Figure 10. Statistical calculations were done using SPSS version 18 
(SPSSI« Inc, Chicago, Illinois), the R Project for Statistical Computing, GraphPad Prim 
5.03 (San Diego, California), and graphics were performed by GraphPad and Microsoft 
Office© Excell 2007.  
P-values lower than 0.05 were considered as statistically significant.  
  
 
 
 
 
 
 
 
 
 
6. Results
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6.1. Different genotypes for rs2304277 in the population 
Genotyping results allowed the determination of the estimate relative 
frequencies of the different genotypes in the population analysed. The Table 4 and 
Annex 2 represents all the mentioned values and percentages obtained by genotyping.  
With a sample of 223, 146 were homozygote for the common allele (G/G), 71 
heterozygous (G/A) and only 6 homozygote for the minor allele (A/A). The minor allele 
is present in 34.5% of the population. These results meet what was reported in Osorio, 
Milne et al. (2014) and dbSNP (2010). 
Within the control group (no mutations in the BRCA genes), wherein 26 were 
heterozygous (G/A) and 4 homozygote for the minor allele (A/A) 31% of the sample 
corresponded to controls, the minor allele is present in  
From those 223 samples, 45 and 49 harboured a mutation in BRCA1 and 
BRCA2, respectively. From the BRCA1 mutation group 14 were heterozygous (G/A), 
representing 31% of all BRCA1 mutation carriers, and from the BRCA2 mutation group 
17, representing 35% of all BRCA2 mutation carriers. 
The 61 samples categorized as BRCAX, 16 had the minor allele representing 
26.6% of the BRCAX group.  Wherein 14 were heterozygous (G/A) and 2 homozygote 
for the minor allele (A/A). 
 
 
6.2. Levels of OGG1 mRNA is reduced in minor allele 
carriers for the rs2304277 variant 
Taking into consideration the first aim of the work, OGG1 mRNA was quantified 
by qPCR in the different groups of the sample.  
 Primarily, concerning their BRCA status and its rs2304277 genotype the 
analysis of the OGG1 mRNA expression levels showed that the group of individuals that 
carrier the minor allele (heterozygous or homozygote for the minor allele) seem to have 
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lower mean levels of OGG1 mRNA, independently of their status or type of BRCA 
mutation (Figure 6.18, Annex 2). Statistical analysis obtained by using unpaired t-test, 
revealed significant differences in the expression between the carriers and non-carriers 
of the minor allele (A) in the Controls and mutated BRCA2 group (p=0.025 and p=0.04, 
respectively) (Figure 6.18).  Since all samples with a minor allele presented lower mean 
of OGG1 mRNA independently of their status or BRCA gene mutated, we can can 
either assume BRCA mutated or not, does not influence the OGG1 mRNA expression.  
Such curious results leaded us to analyse and compare the OGG1 transcript 
levels regardless their status or BRCA mutated gene and only looking into their 
rs2304277 genotype (Figure 6.19).  Interestingly, we found that the group of the carriers 
of the minor allele (A) have significant lower mean OGG1 transcript levels compared 
with the non-carriers, as we could predict by the previous analysis. By using Mann-
Whitney U test, it was possible to see that the difference of the mRNA expression 
between the carriers and the non-carriers of the minor allele (A) were statistically 
significant: p= 0.013 (Figure 6.19). 
We can infer the presence of the minor allele per se has a modifier effect at the 
OGG1 transcript levels, being possible to identify a constant pattern of lower OGG1 
mRNA levels when compared with the non-carriers of the minor allele, regardless their 
status or BRCA gene mutated. 
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Table 4 Number and relative frequencies of the different series within the sample (n=223). K%%over the total 
population” represents their relative frequencies over the sample (n=223) and the “% within its group” represents their 
relative frequencies within the groups which are inserted according with their BRCA mutation status or controls. 
 n 
% over the total 
population 
% within 
its group 
Total  223 100 
 
Homozygote for the common allele (G/G) 146 65.5 
Heterozygous (G/A) 71 31.8 
Homozygote for the minor allele (A/A) 6 2.7 
Controls 68 30.5  
Homozygote for the common allele (G/G) 38 17.0 55.9 
Heterozygous (G/A) 26 11.7 38.2 
Homozygote for the minor allele (A/A) 4 1.8 5.9 
BRCA1 45 20.2  
Homozygote for the common allele (G/G) 31 13.9 68.9 
Heterozygous (G/A) 14 6.3 31.1 
BRCA2  49 22.0  
Homozygote for the common allele (G/G) 32 14.3 65.3 
Heterozygous (G/A) 17 7.6 34.7 
BRCAX 61 27.4  
Homozygote for the common allele (G/G) 45 20.2 73.8 
Heterozygous (G/A) 14 6.3 23 
Homozygote for the minor allele (A/A) 2 0.9 3.3 
 
 
 
 
 Page | 46  
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3. Accelerated telomere shortening in individuals who 
carry the minor allele and a BRCA1/2 mutation 
Knowing the role of OGG1 in the maintenance of the telomere homeostasis and 
its length (Lu and Liu 2010, Jacobs and Schar 2012), we measured the length of the 
telomeres in the leucocytes by high throughput Q-FISH to check whether they were 
shorter in the presence of the minor allele (A), since they also showed less OGG1 
mRNA expression levels. 
Initially, we have evaluated the telomere length distribution of 40 women (Annex 
1, left picture) and 28 healthy men (Annex 1, right picture) as a function of age, in order 
to obtain a regression line to adjust the TL (Kb) of the FBOC individuals analysed. As 
expected, we found a decrease in the TL with age (Annex 1). Test for the equality 
Figure 6.18 Carriers of the rs2304277 minor allele (A) show 
decreased OGG1 mRNA expression levels in all groups. Relative 
OGG1 mRNA expression was significantly different between the 
non- and carriers of the minor allele (A) in the Controls and 
BRCA2 mutated group (p=0.025 and p=0.04, respectively), 
where the carriers the show less OGG1 mRNA levels. Even 
without statistical significance, it is possible to see a decrease in 
the relative OGG1 mRNA expression in the carriers of the minor 
Allele (A) compared with the non-carriers of the BRCA1 and 
BRCAX groups.  
Figure 6.19 Carriers of the rs2304277 minor allele (A) show 
lower relative OGG1 mRNA expression compared with the 
non-carriers. Relative OGG1 mRNA expression between 146 
individuals non-carriers and 77 individuals carriers of the minor 
allele is statistically different (p=0.013). The mean expression in 
the carriers of the minor allele is lower. 
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between the two regression slopes was calculated using “R” according with 
predesigned scrip.    
We have analysed the possible effect of the minor allele on the TL and 
interestingly, as we predicted, the analysis revealed a contribution of the presence of 
the allele (A) in TL. In the Figure 6.20, we can see the rate of TL decay with age 
between the different groups, and individuals that harbour BRCA1/2 mutations together 
with the minor allele (A) displayed a significantly accelerated telomere shortening during 
lifetime compared with the controls and the group of individual that harbour the 
condition (G/G) and a BRCA1/2 mutation  (p<0.0001).  
Thus, we aimed to test whether a faster telomere shortening would also drag to 
a shorter telomere length phenotype. Our results confirmed that indeed happened, in 
which TL was significantly shorter in the individuals that harboured the minor allele (A) 
together with a BRCA mutation compared to the Controls (p=0.034) and even not 
statistically significant, to the group of individuals that harbour the condition (G/G) and a 
BRCA1/2 mutation (Figure 6.21). 
Thus, we tested whether the displayed faster telomere shortening in the 
individuals harbouring BRCA1/2 mutation plus the minor allele (A) could lead to a 
shorter telomere length phenotype. Interestingly, our results confirmed this accelerated 
telomere shortening also that leaded to a short telomere length phenotype, which was 
statistically significant compared to the Controls (p=0.034) and, even if not statistically 
different, with the BRCA1/2 mutation carriers  homozygote for the common allele (G/G), 
we found therefore a trend.  
Hence, the high throughput Q-FISH results come across with the hypothesis of 
this work, sustaining the concept of an accelerated telomere shortening in the 
individuals that carrier the minor allele (A) plus a BRCA1/2 mutation. Possibly, this may 
explain how the variant rs2304277 showed an association with an increased cancer risk 
together with a BRCA1/2 mutation reported in Osorio, Milne et al. (2014). 
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Figure 6.20 Telomere shortening rate during lifetime in FBOC series and Controls. Distribution of leukocyte telomere 
length as a function of the age from: BRCA1/2 (homozygote for the common allele (G/G), blue), BRCA1/2 carriers of the 
rs2304277 minor allele (A) (red) and Controls in black. Individuals that harbour BRCA1/2 mutations together with the 
rs2304277 minor allele (A) displayed a significantly accelerated telomere shortening during lifetime compared with the 
controls and the group of individual that harbour the (G/G) and a BRCA1/2 mutation (p<0.0001). 
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Figure 6.21 Carriers of the minor allele (A) harbouring a mutation in the 
BRCA1/2 gene show shorter telomeres phenotype. The given telomere length 
after the adjustment to age showed significantly shortened telomeres (p=0.034) 
in the carriers of the rs2304277 minor allele that also harbour a mutation in the 
BRCA1/2 gene compared to controls.  
  
 
 
 
 
 
 
 
 
 
7. Discussion 
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The starting point of this study aimed to understand why the SNP in OGG1 
seemed to increase the risk of developing cancer as reported in Osorio, Milne et al. 
(2014). We have checked whether the reason for this risk modification could involve the 
telomere length. Knowing the OGG1 role and its importance to regulate the oxidation 
consequences among guanines (Thomas, Scot et al. 1997, Wang, Rhee et al. 2010), it 
is reasonable to associate that any impairment in this enzyme may affect the telomeres 
integrity due to their elevate amount of guanines. Dysfunctional telomeres can 
accumulate structural aberrations and abnormal chromosome end-to-end fusions, which 
might initiate or promote tumourigenesis as a consequence of chromosomal instability 
(Cong, Wright et al. 2002, O'Sullivan and Karlseder 2010).  
A polymorphism at 3’UTR can, for instances, influence the mRNA molecule by 
different ways altering the final product of transcript and/or respective translated protein 
(Barrett, Fletcher et al. 2012, Pichon, Wilson et al. 2012).  Thus, the experimental 
approach for this work followed this line of reasoning evaluating the OGG1 mRNA levels 
given their genotype for OGG1, to understand if somehow this variant in 3’UTR would 
show differences in OGG1 mRNA levels. 
 
7.1. OGG1 mRNA expression levels 
Indeed, by qPCR it was possible to see changes in the OGG1 mRNA levels 
between the homozygote for the rs2304277common allele (G/G) and the carriers of the 
minor allele (A). Considering their status: controls or a BRCA gene mutated, we could 
see a pattern of lower expression in the carriers of the minor allele (A) along the 
different groups compared with the respective homozygote for the common allele (G/G). 
This shows the OGG1 transcript levels are not dependent/influenced by their status 
(Controls or a BRCA gene mutated) (Figure 6.18). This analysis allowed us to discard 
any influence that BRCA status might have in OGG1 transcription. 
Such curious results leaded us to analyse and compare the OGG1 transcript 
levels between all the individuals that were homozygote for the common allele (G/G) 
and the individuals with the minor allele (G/A) or (A/A), not taking into consideration 
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their status (Controls or a BRCA gene mutated). It is worth to note that we found that 
the group of the carriers the minor allele (A) had significant lower mean OGG1 transcript 
levels compared with the non-carriers (p= 0.013) (Figure 6.19). On top of all these 
findings, this approach allowed us to make another observation, despite a lower mean 
OGG1 mRNA amount among the carriers of the minor allele (A) they also seem to not 
be able to overexpress it. The Figure 6.19 shows that the homozygotes for the common 
allele (G/G) cohort has a wide range of different levels of OGG1 mRNA expression in 
contrast to the carriers of the minor allele (A), who seem to have lower and not much 
more of its expression. Is not possible to make that inference with this study, but is 
something that should be addressed as future work. 
Overall, we can assume that the presence of the minor allele (A) per se has a 
modifier effect at the OGG1 transcript levels, leading to their decrease. This might be a 
post-transcriptional effect due to a greater affinity with regulatory proteins or higher 
instability of the mRNA molecule, which could be addressed as future work. 
 
7.2. Telomere length 
Insofar as OGG1 mRNA seems impaired in individuals who carry the minor 
allele (A) and regarding the coding enzyme function, the measurement of the TL of the 
same sample group used above was certainly a reasonable approach to meet our 
hypothesis and to answer the biological question we were working on.  
Interestingly, the given results by High Throughput Q-FISH showed the 
presence of the minor allele (A) can indeed accelerate the telomere shortening, 
sustaining our hypothesis. Although, the minor allele (A) per se is not sufficient, 
requiring a BRCA mutation but, also a BRCA mutation alone is not sufficient to drag an 
accelerated shortening. In other words, an accelerated telomere shortening is 
observable in individuals who have both a BRCA mutation and carry the minor allele (A) 
of the variant rs2304277 (Figure 6.20). Not only have they showed an accelerated 
telomere shortening but also shorter telomere phenotype (Figure 6.21). The impairment 
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of the OGG1 mRNA and consequently its translation is not sufficient for an accelerated 
telomere shortening or shorter telomere phenotype, being necessary an impaired BRCA 
gene. 
This phenomenon can be explained by the fact that an impaired HR DNA repair 
mechanism due to a BRCA mutation can make the individuals more dependent on other 
members of the DNA repair machinery as BER, in this specific case, OGG1. Also, 
oxidative stress and its effect over the DNA/telomeres is well-described in the literature 
as a promoter of genomic instability when not properly corrected (Oikawa and 
Kawanishi 1999, von Zglinicki 2002, Klaunig, Kamendulis et al. 2010). The individuals 
who show less expression of OGG1 mRNA - the carriers of the minor allele (A) - may 
have a less efficient manner to correct the damage caused by the oxidative stress over 
G-enriched structures as telomeres. Therefore under oxidative stress conditions they 
can have a higher contribution to an accelerated telomeres shortening, when other DNA 
repair mechanism is impaired, as HR. This can lead to chromosomal instability and later 
to carcinogenesis, and like that meeting the premise described in Osorio, Milne et al. 
(2014): rs2304277 shows an association with cancer risk in patients with BRCA 
mutations.  
Knowing BRCA1 and BRCA2 have a role in the telomere homeostasis (Ballal, 
Saha et al. 2009, Badie, Escandell et al. 2010), their deficiency might affect telomeres 
length, making this effect more evident in the presence of a variant in OGG1 that 
appears to affect its mRNA expression levels is also present.  
 
7.3. Advantages and disadvantages of using peripheral 
blood  
Collection of peripheral blood is a very cheap and non-traumatic procedure. 
That procedure is made for diagnosis purposes and what is left can be also used for 
research purposes. Since we are looking forward to making a functional 
characterization of a germinal polymorphism, we can easily evaluate phenotypic 
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differences between the different genotypes (G/G) (G/A) (A/A) just using peripheral 
blood.  
However, peripheral blood collection also faces some disadvantages regarding 
what we want to investigate. Since we are exploring a possible effect of the variant in 
the risk of developing cancer, it would put this study closer from its hypothesis if we had 
tumour samples from carriers of the minor allele (A) to check whether the OGG1 mRNA 
was down-regulated or not, and if those samples showed more chromosomal 
instability/aberrant genomic fusions when compared with cancers that were homozygote 
for the common allele (G/G).  
Concerning the balance between the advantages and disadvantages of this 
study, we can claim that the advantages are greater providing us a successful 
experiment with very interesting outcomes. It will be obviously necessary more work to 
prove our hypothesis with more accuracy.  
  
 
 
 
 
 
 
 
 
 
8. Conclusions 
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Carrying an inherited mutation in BRCA genes predisposes to breast, ovarian 
and even other cancers, however there are considerable differences in the 
manifestation of the disease. The fact is, that not all the individuals that inherited a 
BRCA mutation develop cancer, suggesting the existence of other genetic or 
environmental factors modifying the risk of develop cancer (Couch, Nathanson et al. 
2014).   
As we have foreseen, we found by the genotyping results,  the minor allele 
((G/A) or (A/A) ) of the OGG1 variant rs2304277 is present in 34.5% of the population, 
as reported in Osorio, Milne et al. (2014) e dbSNP (2010). With respect to the OGG1 
mRNA expression levels, diminished levels were observed in the carriers of the minor 
allele (A) when compared to the non-carriers (homozygote for the common allele 
(G/G)), indicating a possible influence of the variant in the regulation of the mRNA 
molecule since it is located in a regulatory region: 3’UTR. Thus, we aimed to analyse 
the possible influence of the polymorphism over the TL, since there is an impairment in 
the OGG1 mRNA levels. 
 The TL analysis showed that individuals that harbour a BRCA mutation plus  
rs2304277 minor allele (A) have a significant accelerated telomere shortening 
(p<0.0001) and not only, they also show shorter TL when compared with the Controls 
(p=0.034) and BRCA1/2 mutation group.  Hence, we are facing a synergetic effect 
between both genetic conditions over the TL, promoting its shortening. The impairment 
of the OGG1 mRNA and consequently its translation is not sufficient for an accelerated 
telomere shortening or shorter telomere phenotype, being necessary an impaired BRCA 
gene. That said, we can assume the presence of the minor allele (A) makes this effect 
more evident in carriers of a BRCA gene mutation.  
It is worth noting that our findings may explain in some means how the variant 
rs2304277, more specifically the presence of the minor allele (A),  can modify the risk of 
developing cancer and perhaps influence the manifestation of the disease among the 
individuals that harbour a BRCA mutation.  Considering the key role of the OGG1 
enzyme in the repair of oxidized DNA (Radicella, Dherin et al. 1997) and the critical role 
of BRCA1 and BRCA2 in various cellular processes, as the maintenance of the 
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telomere homeostasis (Ballal, Saha et al. 2009, Badie, Escandell et al. 2010), it Is 
reasonable to consider that individuals with both systems impaired are more prone to 
develop cancer as a consequence of genomic instability from critically shorter 
telomeres. 
Due to such small amount of individuals homozygotes for the minor allele (A/A) 
(6individuals)  included in the sample used, we cannot confirmed if being homozygote 
for the minor allele gives a higher risk of developing cancer compared to the individuals 
that are heterozygous. Our experiments did not explored that aspect either. 
Overall, such results meet our hypothesis, where the increase of cancer risk 
might be do is due to a less effective OGG1 action over the oxidative stress 
consequences due to a diminished OGG1 mRNA levels. A weaker response upon the 
oxidative stress aggression over the DNA, more specifically structures enriched in 
guanines as telomeres, might favour an accelerated telomere shortening. 
Nonetheless, there is future work to address to find if indeed this is the causal 
variant. The association of this variant with an increased risk to develop ovarian cancer 
in BRCA1 mutation carriers was obtained by a tagSNP approach. As known, this 
approach uses a set of representative SNP in a determined region of the genome with 
high LD with a group of other SNPs. It will be necessary to do an approach with a 
greater resolution as Fine Mapping, to find if the causal variant is the one mentioned in 
this study or any other in LD with rs2304277. 
More experiments are underway towards our hypothesis. Using patient-derived 
lymphoblastoid cells, we are using a concentration time-course of H2O2 treatments to 
understand how OGG1 mRNA is regulated according with the different conditions of 
concentration and time exposure, depending on the BRCA mutation status and 
presence or not of the variant. H2O2 is very commonly used in research for oxidative 
stress studies and in that way we can easily manipulate the conditions in cell culture. As 
well as the OGG1 mRNA expression levels evaluation, the TL and 8-oxoG levels will be 
considered. We do believe these experiments will enrich considerably our conclusions 
towards what we aim to answer. 
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Annexe 1 TL distribution in peripheral blood mononuclear cells as a function of age for healthy female (n=40) 
and healthy men (n=28).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexe 2 Table with the results obtained by genotyping and qPCR. In blue are represented all the samples that 
harbour a mutation in BRAC1, in green a mutation in BRCA2, in red a mutation in BRCAX and finally in black the 
controls. The individuals indicated as “common allele” are homozygote for the common allele (G/G); the 
“heterozygous” are the ones that carry both allele (G/A) and “minor allele” (highlighted in bold) are homozygote for 
(A/A). 
Sample ID Genotype BRCA status Mean ΔCt 
11s1134 Common Allele BRCA1 2.33539192 
11s1272 Common Allele BRCA1 1.99251687 
11s1385 Common Allele BRCA1 1.49312070 
12s1023 Common Allele BRCA1 1.12142309 
12s1058 Common Allele BRCA1 1.42053089 
12s1059 Common Allele BRCA1 1.71387709 
12s108 Common Allele BRCA1 0.52497891 
12s1262 Common Allele BRCA1 0.54841164 
12s1263 Common Allele BRCA1 1.34956208 
12s150 Common Allele BRCA1 1.77439774 
12s23 Common Allele BRCA1 0.67939905 
14S333 Common Allele BRCA1 1.50901106 
12s251 Common Allele BRCA1 0.69861468 
12s745 Common Allele BRCA1 0.66421933 
12s816 Common Allele BRCA1 1.91799326 
12s969 Common Allele BRCA1 1.77071384 
12s970 Common Allele BRCA1 4.59146755 
12s991 Common Allele BRCA1 4.70371819 
13s113 Common Allele BRCA1 3.10143717 
13s114 Common Allele BRCA1 1.07350652 
13s261 Common Allele BRCA1 0.09508312 
13s397 Common Allele BRCA1 1.25427348 
13s424 Common Allele BRCA1 0.27174598 
13s426 Common Allele BRCA1 0.36941936 
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13s539 Common Allele BRCA1 3.91278141 
13s541 Common Allele BRCA1 1.71276919 
14s154 Common Allele BRCA1 0.87794465 
14s250 Common Allele BRCA1 0.96998341 
14S528 Common Allele BRCA1 1.43197670 
14s561 Common Allele BRCA1 1.2369724 
14S934 Common Allele BRCA1 1.77536388 
11s1111 Common Allele BRCA2 0.77150054 
11s1276 Common Allele BRCA2 1.220381604 
11s1277 Common Allele BRCA2 0.372762849 
12s1055 Common Allele BRCA2 2.002941487 
12s1056 Common Allele BRCA2 0.522437879 
12s1057 Common Allele BRCA2 2.462853681 
12s1064 Common Allele BRCA2 3.425514661 
12s1065 Common Allele BRCA2 1.596171034 
12s1069 Common Allele BRCA2 3.032130955 
12s1167 Common Allele BRCA2 2.910627349 
12s1193 Common Allele BRCA2 1.574976674 
12s1259 Common Allele BRCA2 5.066271927 
12s152 Common Allele BRCA2 1.098345474 
12s153 Common Allele BRCA2 3.676492481 
12s2 Common Allele BRCA2 0.543869328 
12s646 Common Allele BRCA2 1.477846294 
12s649 Common Allele BRCA2 1.081754305 
12s746 Common Allele BRCA2 1.668807186 
12s748 Common Allele BRCA2 1.849750659 
13S1031 Common Allele BRCA2 2.033109372 
13s305 Common Allele BRCA2 2.377053665 
13s388 Common Allele BRCA2 0.224656676 
13s392 Common Allele BRCA2 0.928910283 
13s431 Common Allele BRCA2 2.84421434 
13s538 Common Allele BRCA2 1.588130638 
13s726 Common Allele BRCA2 0.486882605 
14s117 Common Allele BRCA2 0.524670037 
14s119 Common Allele BRCA2 1.468010234 
14s225 Common Allele BRCA2 0.914177508 
14s252 Common Allele BRCA2 1.325840854 
14s476 Common Allele BRCA2 2.518780926 
14s988 Common Allele BRCA2 1.308879397 
11s1015 Common Allele BRCAX 0.14174123 
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11s1131 Common Allele BRCAX 1.09984043 
11s1176 Common Allele BRCAX 1.10447845 
11s1194 Common Allele BRCAX 1.22086701 
11s1271 Common Allele BRCAX 0.43203806 
12s1192 Common Allele BRCAX 1.43170145 
12s253 Common Allele BRCAX 1.44033509 
12s27 Common Allele BRCAX 0.77103242 
12s29 Common Allele BRCAX 0.55893833 
12s30 Common Allele BRCAX 1.50930494 
12s360 Common Allele BRCAX 0.97670586 
12s708 Common Allele BRCAX 2.39217400 
12s747 Common Allele BRCAX 1.51525873 
12s926 Common Allele BRCAX 1.36463603 
12s927 Common Allele BRCAX 1.06018393 
12s928 Common Allele BRCAX 1.57491122 
13s1175 Common Allele BRCAX 2.76553840 
13s1177 Common Allele BRCAX 0.60352408 
13S1180 Common Allele BRCAX 0.99083308 
13S1257 Common Allele BRCAX 0.35142794 
13s1258 Common Allele BRCAX 1.74974958 
13s1262 Common Allele BRCAX 0.67087918 
13s1316 Common Allele BRCAX 0.68446840 
13s1347 Common Allele BRCAX 0.60528449 
13s243 Common Allele BRCAX 3.94549954 
13S260 Common Allele BRCAX 4.32757604 
13s512 Common Allele BRCAX 1.94075545 
13s52 Common Allele BRCAX 1.95944397 
13s535 Common Allele BRCAX 2.55409849 
13S729 Common Allele BRCAX 0.28399218 
13s789 Common Allele BRCAX 0.52634869 
13s793 Common Allele BRCAX 1.47096656 
13s794 Common Allele BRCAX 0.76773454 
13S882 Common Allele BRCAX 0.40219534 
13S884 Common Allele BRCAX 0.70214493 
13s967 Common Allele BRCAX 0.26118926 
14S221 Common Allele BRCAX 2.66179957 
14s473 Common Allele BRCAX 0.53297049 
14s813 Common Allele BRCAX 1.72250349 
14s224 Common Allele BRCAX 0.70482430 
14s563 Common Allele BRCAX 3.49529638 
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14S587 Common Allele BRCAX 0.44137412 
14S588 Common Allele BRCAX 0.96954516 
14s812 Common Allele BRCAX 3.14692931 
14s869 Common Allele BRCAX 3.13880444 
11s1011 Common Allele control 0.029462372 
11s1274 Common Allele control 1.62007555 
11s1275 Common Allele control 0.092611118 
12s1022 Common Allele control 2.230861326 
12s1024 Common Allele control 1.974027882 
12s1060 Common Allele control 2.021366706 
12s1067 Common Allele control 1.599778591 
12s1068 Common Allele control 1.843349643 
12S1260 Common Allele control 4.688377147 
12S1261 Common Allele control 2.24348156 
12s171 Common Allele control 0.931953897 
12s252 Common Allele control 1.332190896 
12s650 Common Allele control 1.639372193 
12s651 Common Allele control 1.768316902 
12s742 Common Allele control 1.99752429 
13S1033 Common Allele control 1.227781715 
13S1179 Common Allele control 2.742431962 
13s1317 Common Allele control 1.22072597 
13s1344 Common Allele control 0.839552595 
13S258 Common Allele control 2.444016632 
13s302 Common Allele control 3.168116844 
13s303 Common Allele control 3.226806952 
13S304 Common Allele control 4.622182366 
13s425 Common Allele control 2.003149844 
13s654 Common Allele control 0.322451636 
13S731 Common Allele control 0.418561679 
13S791 Common Allele control 0.29132392 
13s792 Common Allele control 0.789637514 
13s838 Common Allele control 5.161315747 
13S883 Common Allele control 0.228180791 
13s98 Common Allele control 3.356649929 
14S155 Common Allele control 0.498695202 
14s222 Common Allele control 1.384121345 
14s226 Common Allele control 3.65289493 
14s770 Common Allele control 1.56624771 
14S809 Common Allele control 4.439767932 
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14s814 Common Allele control 2.037915032 
14s815 Common Allele control 3.475344028 
12s148 Heterozygous BRCA1 1.79474165 
12s149 Heterozygous BRCA1 0.94039116 
12s169 Heterozygous BRCA1 0.89878916 
12s568 Heterozygous BRCA1 1.68053840 
12s569 Heterozygous BRCA1 1.37513726 
13s1072 Heterozygous BRCA1 1.65752494 
13s112 Heterozygous BRCA1 1.83157798 
13s1178 Heterozygous BRCA1 0.60902285 
13S559 Heterozygous BRCA1 0.26513026 
13s67 Heterozygous BRCA1 1.06682991 
13s68 Heterozygous BRCA1 2.76303584 
14S220 Heterozygous BRCA1 1.53568083 
14s562 Heterozygous BRCA1 1.69006798 
13s430 Heterozygous BRCA1 + 
BRCA2 
1.08370106 
11s1268 Heterozygous BRCA2 1.850284539 
14s472 Heterozygous BRCA2 0.721208789 
11s1269 Heterozygous BRCA2 0.549553317 
11s1270 Heterozygous BRCA2 0.245044307 
12s1 Heterozygous BRCA2 0.141510646 
12s1052 Heterozygous BRCA2 1.447907917 
12s1054 Heterozygous BRCA2 0.81728245 
12s1061 Heterozygous BRCA2 2.495505228 
12s3 Heterozygous BRCA2 0.576475662 
13s1181 Heterozygous BRCA2 0.110584261 
13s1346 Heterozygous BRCA2 1.108603293 
13s393 Heterozygous BRCA2 1.841930932 
13s655 Heterozygous BRCA2 0.880391061 
13S837 Heterozygous BRCA2 1.886430723 
13s430 Heterozygous BRCA1 + 
BRCA2 
1.083701065 
14S811 Heterozygous BRCA2 1.715163862 
14s838 Heterozygous BRCA2 0.264540853 
11s1012 Heterozygous BRCAX 1.64102007 
11s1195 Heterozygous BRCAX 0.99323995 
12s1132 Heterozygous BRCAX 1.75176798 
12s645 Minor Allele BRCAX 1.44880366 
12s990 Heterozygous BRCAX 2.05000028 
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13s1314 Heterozygous BRCAX 0.59041695 
13S1319 Heterozygous BRCAX 0.64822599 
13s1345 Heterozygous BRCAX 0.44303309 
13s1382 Heterozygous BRCAX 0.63417147 
13s447 Minor Allele BRCAX 1.33932134 
13S612 Heterozygous BRCAX 0.31138108 
13S728 Heterozygous BRCAX 0.93235758 
13S730 Heterozygous BRCAX 0.58027720 
14S114 Heterozygous BRCAX 3.35080395 
14s531 Heterozygous BRCAX 0.39809928 
14s532 Heterozygous BRCAX 0.82721233 
11s1193 Heterozygous control 0.538708 
12s10 Heterozygous control 1.009283 
12s1050 Minor Allele control 2.395505 
12s1051 Minor Allele control 1.106145 
12s1062 Heterozygous control 1.604241 
12s1066 Heterozygous control 2.910631 
12s170 Heterozygous control 1.096323 
12s8 Minor Allele control 1.275292 
13S1032 Heterozygous control 1.085633 
13s1073 Heterozygous control 0.293654 
13s1261 Minor Allele control 1.897319 
13s299 Heterozygous control 0.827024 
13S300 Heterozygous control 1.510594 
13s301 Heterozygous control 1.498766 
13s443 Heterozygous control 0.491523 
13s446 Heterozygous control 0.232666 
13S836 Heterozygous control 1.77724 
13s880 Heterozygous control 0.0866 
13s99 Heterozygous control 0.960815 
14s120 Heterozygous control 0.898681 
14s121 Heterozygous control 1.020974 
14s122 Heterozygous control 0.584356 
14s253 Heterozygous control 1.730081 
14s474 Heterozygous control 3.192469 
14s526 Heterozygous control 0.73501 
14s533 Heterozygous control 0.564623 
14s534 Heterozygous control 0.931532 
14s839 Heterozygous control 1.880791 
14s840 Heterozygous control 2.558008 
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14s868 Heterozygous control 1.504775 
 
